The DOI matches its Crossref record.
Hybrid Dendrimer Hydrogel/PLGA Nanoparticle Platform Sustains Drug Delivery for One Week and Antiglaucoma Effects for Four Days Following One-Time Topical Administration
Abstract
We report a novel hybrid polyamidoamine (PAMAM) dendrimer hydrogel/poly(lactic-co-glycolic acid) (PLGA) nanoparticle platform (HDNP) for codelivery of two antiglaucoma drugs, brimonidine and timolol maleate. This platform was not cytotoxic to human corneal epithelial cells. Cellular uptake of Nile red-encapsulating PLGA nanoparticles was significantly increased by dendrimer hydrogel. A prolonged residence time of nanoparticles was demonstrated through investigation of FluoSpheres loaded into dendrimer hydrogel. Both brimonidine and timolol maleate were slowly released in vitro over a period of 28-35 days. Following topical administration of one eye drop (30 μL of 0.7% w/v brimonidine and 3.5% w/v timolol maleate) in normotensive adult Dutch-belted male rabbits, the HDNP formulation resulted in a sustained and effective IOP reduction (18% or higher) for 4 days. Furthermore, the HDNP maintained significantly higher concentrations of brimonidine in aqueous humor and cornea as well as timolol maleate in the aqueous humor, cornea, and conjunctiva up to 7 days as compared to saline, DH, and PLGA nanoparticle dosage forms, without inducing ocular inflammation or discomfort. Histological analysis of the cornea and conjunctiva did not reveal any morphological or structural changes. Our work demonstrated that this new platform is capable of enhancing drug bioavailability and sustaining effective IOP reduction over an extended period of time. This newly developed platform can greatly reduce dosing frequency of topical formulations, thus, improving long-term patient compliance and reducing enormous societal and economic costs. Given its high structural adaptability, many other chronic ocular diseases would benefit from long-lasting drug delivery of this new platform.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jang, S. C., Kim, O. Y., Yoon, C. M., Choi, D.-S., Roh, T.-Y., Park, J., Nilsson, J., Lötvall, J., Kim, Y.-K., & Gho, Y. S. (2013) · ACS Nano · doi:10.1021/nn402232g · Cited by 1,022
Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications
Kannan, R. M., Nance, E., Kannan, S., & Tomalia, D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12280 · Cited by 542
Zhou, X., Qiao, J., Yang, L., & Zhang, J. (2014) · Advanced Energy Materials · doi:10.1002/aenm.201301523 · Cited by 498
Dendrimer-based drug delivery systems: history, challenges, and latest developments
Wang, J., Li, B., Qiu, L., Qiao, X., & Yang, H. (2022) · Journal of Biological Engineering · doi:10.1186/s13036-022-00298-5 · Cited by 406
Self-citationZhao, F., Yao, D., Guo, R., Deng, L., Dong, A., & Zhang, J. (2015) · Nanomaterials · doi:10.3390/nano5042054 · Cited by 400
Metadata
- Authors
- Yang, H., Tyagi, P., Kadam, R. S., Holden, C. A., & Kompella, U. B.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-08-21
- Volume
- 6
- Issue
- 9
- Pages
- 7595-7606
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2077707761
- Cited by
- 207
- References
- 0
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hybrid Dendrimer Hydrogel/PLGA Nanoparticle Platform Sustains Drug Delivery for One Week and Antiglaucoma Effects for Four Days Following One-Time Topical Administration. https://app.cochat.ai/papers/10.1021/nn301873v
- The paper
- Yang, H., Tyagi, P., Kadam, R. S., Holden, C. A., & Kompella, U. B. (2012). Hybrid Dendrimer Hydrogel/PLGA Nanoparticle Platform Sustains Drug Delivery for One Week and Antiglaucoma Effects for Four Days Following One-Time Topical Administration. ACS Nano. https://doi.org/10.1021/nn301873v
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.